



## Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

February 26, 2026

MORRISTOWN, N.J., Feb. 26, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced participation at the following investor conferences:

- **TD Cowen 46th Annual Health Care Conference** – Dave Lennon, PhD, President and CEO, will participate in a hybrid presentation and fireside chat on Tuesday, March 3 at 10:30 AM ET
- **Leerink 2026 Global Healthcare Conference** – executives will participate in investor meetings on Monday, March 9
- **Citizens Life Sciences Conference** – Dave Lennon, PhD, President and CEO, will give a corporate presentation on Tuesday, March 10 at 12:30 PM ET

A live webcast of the TD Cowen and Citizens presentations can be accessed by visiting the Whitehawk Therapeutics IR [website](#) and will be available for replay for approximately 30 days following the event.

### About Whitehawk Therapeutics

Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at [www.whitehawktx.com](http://www.whitehawktx.com) and connect with us on LinkedIn.

### Contact:

[IR@whitehawktx.com](mailto:IR@whitehawktx.com)



View original content to download multimedia: <https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-upcoming-investor-conferences-302697787.html>

SOURCE Whitehawk Therapeutics, Inc.